Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Canada.
Leuk Lymphoma. 2021 May;62(5):1046-1056. doi: 10.1080/10428194.2020.1861277. Epub 2020 Dec 25.
The evolving CoViD-19 pandemic has raised unprecedented challenges for physicians who face significant constraints in medical resources and cancer therapies. The management of patients with lymphoma represents a unique challenge given the heterogeneity of the patient population and treatment goals as well as the myriad choices of therapy available to clinicians. Adaptation in clinical practice with the goal of maintaining appropriate continuity and quality of care while mitigating exposure risk has forced clinicians around the world to develop new standards of practice and can pose difficult ethical choices in vulnerable patient populations. Based on recommendations formulated by several medical groups and societies, this article provides an overview of the general and specific practical considerations that apply to the care of lymphoma patients during the outbreak. We hope to provide a practical framework to help guide physicians in their therapeutic choices and facilitate the ongoing management of this specific patient population.
不断演变的 COVID-19 大流行给面临医疗资源和癌症治疗严重限制的医生带来了前所未有的挑战。由于患者人群的异质性和治疗目标的不同，以及临床医生可获得的多种治疗选择，淋巴瘤患者的管理是一项独特的挑战。为了在减轻暴露风险的同时保持适当的连续性和护理质量，临床实践需要进行调整，这迫使世界各地的临床医生制定新的实践标准，并可能给弱势患者群体带来困难的伦理选择。基于几个医学组织和协会制定的建议，本文概述了适用于大流行期间淋巴瘤患者护理的一般和具体实际考虑因素。我们希望提供一个实用的框架，帮助指导医生做出治疗选择，并促进对这一特定患者群体的持续管理。
